Correlates of In-Hospital Deaths among Hospitalizations with Pulmonary Embolism: Findings from the 2001–2008 National Hospital Discharge Survey

James Tsai*, Scott D. Grosse, Althea M. Grant, Nimia L. Reyes, W. Craig Hooper, Hani K. Atrash

Division of Blood Disorders, National Center on Birth Defects and Developmental Disabilities Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America

Abstract

Background: Deep vein thrombosis and pulmonary embolism (PE) are responsible for substantial mortality, morbidity, and impaired health-related quality of life. The aim of this study was to evaluate the correlates of in-hospital deaths among hospitalizations with a diagnosis of PE in the United States.

Methods: By using data from the 2001–2008 National Hospital Discharge Survey, we assessed the correlates of in-hospital deaths among 14,721 hospitalizations with a diagnosis of PE and among subgroups stratified by age, sex, race, days of hospital stay, type of admission, cancer, pneumonia, and fractures. We produced adjusted rate ratios (aRR) and 95% confidence intervals using log-linear multivariate regression models.

Results: Regardless of the listing position of diagnostic codes, we observed an increased likelihood of in-hospital death in subgroups of hospitalizations with ages 50 years and older (aRR = 1.82 - 8.48), less than 7 days of hospital stay (aRR = 1.43 - 1.57), cancer (aRR = 2.10 - 2.28), pneumonia (aRR = 1.79 - 2.20), or fractures (aRR = 2.18) (except for first-listed PE), when compared to the reference groups with ages 1 - 49 years, 7 days or more of hospital stay, without cancer, pneumonia, or fractures while adjusting for covariates. In addition, we observed an increased likelihood of in-hospital death for first-listed PE in hospitalizations of women, when compared to those of men (aRR = 1.45).

Conclusions: The results of this study provide support for identifying, developing, and implementing effective, evidencebased clinical assessment and management strategies to reduce PE-related morbidity and mortality among hospitalized PE patients who may have concurrent health conditions including cancer, pneumonia, and fractures.

Citation: Tsai J, Grosse SD, Grant AM, Reyes NL, Hooper WC, et al. (2012) Correlates of In-Hospital Deaths among Hospitalizations with Pulmonary Embolism: Findings from the 2001–2008 National Hospital Discharge Survey. PLoS ONE 7(7): e34048. doi:10.1371/journal.pone.0034048

Editor: Pieter H. Reitsma, Leiden University Medical Center, The Netherlands

Received February 22, 2012; Accepted May 16, 2012; Published July 6, 2012

This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.

Funding: No current external funding received for this study.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: jxt9@cdc.gov

Introduction

Deep vein thrombosis (DVT) and pulmonary embolism (PE) are part of a venous thromboembolism spectrum with a complex and multifaceted etiology involving the interactions of biological, behavioral, health, and environmental risk factors [1-4]. The 2008 Surgeon General's Call to Action to Prevent Deep Vein Thrombosis and Pulmonary Embolism suggests that DVT and PE may contribute to as many as 100,000-180,000 deaths per year [5]. Furthermore, PE can result in substantial morbidities including recurrence, chronic pulmonary hypertension, disability, and impaired health-related quality of life [5-8]. Accumulating evidence suggests that hospitalized patients including those with cancer, pneumonia, and fractures may have a high risk of PE [1,9-11]. These health conditions were found among the leading diagnostic categories and linked to approximately 3.3 million hospitalizations in the United States in 2007 [12]. Recent data from the National Hospital Discharge Survey (NHDS) showed that the overall casefatality rate of hospitalizations with a PE diagnosis declined from 11.4% to 7.1% during 2001-2008, even though a corresponding reduction in the estimated number of in-hospital deaths among such hospitalizations was not observed for the same period [13].

To date, numerous clinical and epidemiologic studies have assessed PE mortality by using data ascertained from death certificates, autopsy records, or participants of clinical investigations [14-17]. A number of studies have assessed the case-fatality rates of PE and the relationship between in-hospital death and risk factors among patients or hospitalizations with a PE diagnosis by using the national hospital discharge surveys [13,18-24]. However, few studies have examined the correlates of in-hospital death, encompassing diagnostic categories of cancer, pneumonia, and fractures, among a nationally representative sample of hospitalizations with a PE diagnosis in the United States. Such a study is valuable to identify risk factors for PE-related death and to provide observational evidence that can inform and improve clinical assessment and intervention strategies for hospitalized PE patients. Therefore, the aim of this study was to assess the correlates of in-hospital death, including demographic characteristics and clinical risk factors, among

hospitalizations with a PE diagnosis (i.e., first-listed and anylisted) in the United States by analyzing data from the 2001-2008 NHDS [25].

Methods

Data Source

The NHDS was conducted annually from 1965-2010 by the National Center for Health Statistics (NCHS), Centers for Disease Control and Prevention (CDC) to collect demographic and medical information of a sample of hospitalizations from a national probability selection of hospitals in the 50 states and the District of Columbia [26]. The NHDS was designed to collect information on characteristics of inpatients discharged from non-Federal short-stay hospitals in the United States. The NHDS includes general or children's general hospitals with an average length of stay of fewer than 30 days for all patients. Federal, military, and Department of Veterans Affairs hospitals were excluded, as were hospital units of institutions and hospitals with fewer than 6 beds staffed for patient use. Details about the survey methodology are available elsewhere [25]. The NHDS collects information of hospitalizations including age, race, sex, length of hospital stay, type of admission (e.g., emergency, urgent, and elective), discharge status (e.g., death), medical diagnosis and procedure codes. Data collection for the NHDS was approved by the NCHS Research Ethics Review Board (NCHS ERB #2011-12). Analysis of deidentified data from the survey is exempt from the federal regulations for the protection of human research participants.

Hospitalization Records

Because persons with multiple hospitalizations during the survey year may be sampled more than once, estimates from the NHDS are for hospitalizations, not for persons. Each sampled hospitalization has a maximum of seven diagnostic codes based on the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM). The first-listed code is a principal diagnosis. We limited our analysis to a sample of non-newborn hospitalizations with a first-listed PE (n = 8,990) or any-listed PE (n = 14,721). Table 1 lists the codes for identification of PE and selected diagnostic categories for the years 2001-2008. In addition to demographic variables (i.e., age, sex, and race), we also included covariates such as cancer, pneumonia, and fractures in the analysis. We included these covariates because they are wellestablished independent risk factors for PE and may represent important pathways for prevention.

Statistical Analysis

We combined 8 years of data to increase statistical reliability and to allow the analysis of some subpopulation groups that otherwise would have been too small to produce statistically reliable estimates [25,27]. We estimated the case-fatality rates in hospitalizations with a diagnosis of PE (i.e., first-listed and anylisted) and in subgroups stratified by age, sex, race, days of hospital stay, type of admission, and status of cancer, pneumonia, and fractures [28]. To examine the associations between in-hospital death and risk factors among hospitalizations with a PE diagnosis during the period 2001–2008, we produced unadjusted and adjusted rate ratios (aRRs) with 95% confidence intervals (CIs) by using demographic and medical risk factors as predictors; status of in-hospital death was used as an outcome variable in multivariate log-linear regression models.

To present all estimates that fully account for multiple stages of sampling, stratification, and clustering design of the NHDS, we accessed the restricted datasets through the Research Data Center (CDC, Atlanta, GA, 2011) [26]. We used SPSS 19 Complex Samples for Survey Analysis (IBM Corp., Armonk, NY, 2010) and STATA 11 (StataCorp LP, College Station, TX, 2009) to perform the data management and analyses to account for complex sample survey design [29].

Results

Except for a limited number of deaths in hospitalizations of fractures with first-listed PE, the case-fatality rates varied significantly by age, status of cancer, pneumonia, and fractures among hospitalizations with first-listed PE and any-listed PE (P<0.05 for Wald-F test). Specifically, the case-fatality rates were higher among hospitalizations with advanced ages, cancer, pneumonia, or fractures than among those with younger ages, without a diagnosis of cancer, pneumonia, or fractures (P<0.05 for Wald-F test) (Table 2). Of those hospitalizations with first-listed PE, we observed increased likelihoods of in-hospital death in subgroups with ages 50-79 years (aRR = 3.63; CI: 1.88-7.02), ages 80 years and older (aRR = 8.48; CI: 4.03-17.90), female (aRR = 1.45; CI: 1.09 - 1.93), less than 7 days of hospital stay (aRR = 1.57; CI: 1.12-2.21), cancer (aRR = 2.28; CI: 0.12)1.68-3.09), or pneumonia (aRR = 2.20; CI: 1.28-3.77), when compared to the reference groups with ages 1-49 years, male, 7 days or more of hospital stay, without cancer or pneumonia while adjusting for all covariates (Table 2). Similarly, of hospitalizations with any-listed PE diagnosis, we observed increased likelihoods of in-hospital death among subgroups with ages 50-79 years (aRR = 1.82; CI: 1.47 - 2.25), ages 80 years and older(aRR = 3.26; CI: 2.58-4.12), race/ethnicity listed under "other" (aRR = 1.36; CI: 1.15 - 1.76), less than 7 days of hospital stay (aRR = 1.43; CI: 1.15 - 1.76), cancer (aRR = 2.10; CI: 0.15 - 0.16)1.74-2.53), pneumonia (aRR = 1.79; CI: 1.48-2.17), or fractures (aRR = 2.32; CI: 1.68 - 3.20), when compared to the reference groups with ages 1-49 years, male, white, 7 days or more of

 Table 1. The International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes for identification of selected medical diagnoses, 2001–2008.

Description	ICD-9-CM codes ^a
Pulmonary embolism	415.1×, 634.6×, 635.6×, 636.6×, 637.6×, 638.6, and 673.2×
Cancer (malignant neoplasm)	140–208, 230–234
Pneumonia	480-486
Fractures	800-829

^aOnly three-digit category codes are listed for cancer, pneumonia, and fractures. doi:10.1371/journal.pone.0034048.t001

States.
United
NHDS,
-2008,
2001
diagnosis,
a PE
with
ospitalizations
ng hc
i amo
death
hospital
or in-
ratios f
d rate
rates an
-fatality
d case
Estimated
e 2.
Tabl

First-listed PE (n= 8,90) First-listed PE (n= 8,90) And Case-fatality Pouloe Mailusted Adjusted And 3550 10 05-19 Ref (95% CI) 363 (188 - 703) S00-79 824 3 (13 - 45) 343 (138 - 703) 363 (188 - 703) S00-79 824 3 (13 - 45) 32 (20 - 73) 363 (188 - 703) S00-79 823 3 (13 - 45) 32 (20 - 73) 363 (188 - 703) S00-79 823 3 (13 - 45) 33 (188 - 703) 363 (188 - 703) S00-79 824 3 (13 - 45) 32 (10 - 19) 84 (03 - 16) S00-79 824 3 (13 - 45) 33 (188 - 703) 363 (188 - 703) S00-79 293 3 (13 - 45) 84 (00 - 103) 14 (10 - 104) 14 (10 - 104) 14 (10 - 104) 14 (10 - 104) 14 (10 - 104) 14 (10 - 104) 14 (10 - 104) 14 (10 - 104) 14 (10 - 104) 14 (10 - 104) 14 (10 - 104) 14 (10 - 104) 14 (10 - 104) 14 (10 - 104) 14 (10 - 104) 14 (10 - 104) 14 (10 - 104)	Am Am Unadjusted Adjusted Cas Uradjusted Adjusted Cas RR ^d (95% CI) R8 ^d (95% CI) (95 RR ^d (95% CI) R8 ^d (95% CI) (95 R8 ^d (95% CI) R8 ^d (95% CI) (95 R8 ^d (95% CI) R8 ^d (95% CI) (95 R8 ^d (95% CI) R8 ^d (95% CI) (95 823 (101 - 7.31) 3.63 (1.88 - 7.02) 8.1 8.23 (4.03 - 16.8) 8.48 (4.03 - 17.9) 13.6 Referent Referent Referent 8.3	r-listed PE (n = 14,721) e-fatality % Cl) P-value P<0.001	Unadjusted RR (95% CI)	1. diucted
n Case-fatality isse (%) sea	Case Case <th< th=""><th>e-fatality e (%) % CI) <i>P-</i>value P<0.001</th><th>Unadjusted //</th><th>Adiusted</th></th<>	e-fatality e (%) % CI) <i>P-</i> value P<0.001	Unadjusted //	Adiusted
Age ρ <0.001	Referent ^f Referent 4.0 3.82 (2.01–7.31) 3.63 (1.88–7.02) 8.1 8.23 (4.03–16.8) 8.48 (4.03–17.9) 13.6 Referent Referent 8.3	P<0.001		R (95% CI)
1-49 350 $10(0,5-1.9)$ Referent ¹ Referent ¹ $20-79$ 824 $38(3,2-45)$ $382(201-7.31)$ $363(1388-702)$ 280 2331 $82(5,8-11,3)$ $82(3,6-1.5)$ $84(403-17)$ 280 2331 $82(3,-45)$ $82(3,-45)$ $84(403-17)$ $Male$ 6224 $31(2,5-31)$ $Referent Referent Male 6234 31(2,5-31) Referent Referent Male 6234 31(2,5-31) Referent Referent Male 6324 31(2,5-31) Referent Referent Male 793 40(3,2-4,9) Referent Referent Male 793 40(3,2-4,9) 92(0,6-1,2) 117(0,80-1,2) Male 2099 35(2,2-4,4) Referent Referent Male 325(2,2-4,3) 23(2,7-4,2) 23(2,7-4,2) 117(0,80-1,2) Male 413,4,51 212(4,5,6) 212(4,5,6) 212(4,5,6) $	Referent ^f Referent 4.0 3.82 (2.01-7.31) 3.63 (1.88-7.02) 8.1 8.23 (4.03-16.8) 8.48 (4.03-17.9) 13.6 Referent Referent 8.3			
$50-79$ $8,24$ $3,8,3,2-4,5$ $3,8,2,20-7,3$ $3,63,(1,8e-7,0)$ ≥ 80 $2,93$ $8,2(5,8-11,3)$ $8,2(3,0-1,5,3)$ $3,63,(1,8e-7,0)$ ≥ 80 $2,93$ $8,1(2,5-3,7)$ $P=0015$ $Refent Refent Aae 8,97 3,1(2,5-3,7) 7=0,015 Refent Refent Male 6,23 3,1(2,5-3,6) 1,46,(1,08-1,96) 1,45,(1,09-1,93) Male 8,97 4,5(3,5-5,6) 1,46,(1,08-1,96) 1,45,(1,09-1,93) Male 2,93 4,03,2-4,60 1,46,(1,08-1,96) 1,46,(1,08-1,96) Mhite 2,93 4,03,2-4,60 2,64,-61,03 1,46,(1,08-1,96) Mhite 2,93 2,2,1-4,20 2,2,1,23 2,2,1,23 Moti stated 4,2,6,-4,26 2,2,1,23 2,2,1,22 2,2,1,22 Moti stated 4,2,6,-4,20 2,2,1,23 2,2,1,22 2,2,1,22 Moti stated 2,2,2,1,23 2,2,2,1,23 2,2,2,1,23 2,2,2,1,22 Moti st$	3.82 (2.01-7.31) 3.63 (1.88-7.02) 8.1 8.23 (4.03-16.8) 8.48 (4.03-17.9) 13.6 Referent Referent 8.3	(3.3-4.8)	Referent	teferent
≥ 00 $2,931$ $8,2(36-11,3)$ $P=0015$ $8,4(4,03-1/5)$ $8,4(4,03-1/5)$ ext $r=1$ $P=0015$ $P=0015$ $Referent$ Referent $Male$ $6,224$ $3,1(2,5-3,7)$ $P=0015$ $Referent$ Referent $Male$ $6,224$ $3,1(2,5-3,7)$ $Referent$ Referent Referent $Male$ $5,23-5,60$ $3,2$ $2,24-3,60$ $1,4,6(1,08-1,96)$ $1,4,6(1,08-1,96)$ $Mate$ $7,33$ $2,033$ $2,032$ $2,6,29-4,60$ $1,17(0.88-1,57)$ $Mate$ $7,332$ $2,6,29-4,60$ $2,2,4-2,60$ $2,1,4-2,60$ $2,1,4-2,60$ Mot $2,293$ $2,1,2-2,51$ $2,2,1-2,51$ $2,2,1-2,51$ $2,2,1-2,51$ Mot $3,2,2-4,2,50$ $2,2,2,2-1,51$ $2,2,2,2,21$ $2,2,2,2,21$ Mot $2,2,2,2,21$ $2,2,2,2,21$ $2,2,2,2,21$ $2,2,2,2,22$ Mot $2,2,2,2,21$ $2,2,2,2,21$ $2,2,2,2,22$ $2,2,2,2,22$ Mot $2,2,3,2,2,22$ <th< td=""><td>8.23 (4.03–16.8) 8.48 (4.03–17.9) 13.6 Referent Referent 8.3</td><td>(7.1–9.1)</td><td>2.02 (1.64–2.49)</td><td>.82 (1.47–2.25)</td></th<>	8.23 (4.03–16.8) 8.48 (4.03–17.9) 13.6 Referent Referent 8.3	(7.1–9.1)	2.02 (1.64–2.49)	.82 (1.47–2.25)
Sex $P=0015$ Referent Male $6,224$ $31, (2,5-3,7)$ Referent Referent Male $6,224$ $31, (2,5-3,7)$ $146(108-1,96)$ $145(1,09-1,93)$ Female $8,497$ $45(3,5-5,6)$ $ -$ Mile 793 $40(32-4,90)$ $ -$ Winte 793 $40(32-4,60)$ $ -$ Winte 793 $40(32-4,60)$ $ -$ Winte 793 $40(32-4,60)$ $ -$ Mot stated 4296 $37(2,4-56)$ $ -$ Wot stated 4296 $37(2,4-56)$ $ -$ Mot stated 793 $42(3,4-51)$ $ -$ State $ -$	Referent Referent 8.3	5 (11.6–16.0)	3.41 (2.67-4.35)	:26 (2.58-4.12)
Male 6224 3.1 (2.5 - 3.7) Referent Referent Female 8497 4.5 (3.5 - 5.6) 1.46 (1.08 - 1.96) 1.45 (1.00 - 1.93) Renale 8497 4.5 (3.5 - 5.6) 1.46 (1.08 - 1.96) 1.45 (1.00 - 1.93) Renale 7.33 4.0 (3.2 - 4.6) $-$ 1.46 (1.08 - 1.96) 1.45 (1.00 - 1.93) Rete 7.33 3.6 (2.9 - 4.6) $-$ 0.92 (0.69 - 1.22) 1.17 (0.88 - 1.57) Black 3.5 $-^{h}$ $-^{h}$ $-^{h}$ $-^{h}$ $-^{h}$ Not stated 3.5 $-^{h}$ $-^{h}$ $-^{h}$ $-^{h}$ $-^{h}$ Other 3.5 $-^{h}$ $-^{h}$ $-^{h}$ $-^{h}$ $-^{h}$ Other 3.5 $-^{h}$ $-^{h}$ $-^{h}$ $-^{h}$ $-^{h}$ $-^{h}$ Other 3.5 $-^{h}$ $-^{h}$ $-^{h}$ $-^{h}$ $-^{h}$ $-^{h}$ Other 3.6 $-^{h}$ $-^{h}$ $-^{h}$ $-^{h}$ $-^{h$	Referent Referent 8.3	P = 0.884		
Female84974.5 (3.5 - 5.6)1.46 (1.08 - 1.96)1.45 (1.09 - 1.93)Rece $ -$ Mine 7.933 4.0 (3.2 - 4.9) $-$ ReferentReferentMine 7.933 4.0 (3.2 - 4.6) $ 0.92 (0.69 - 1.22)$ $1.17 (0.88 - 1.57)$ Black 3.929 $-^{h}$ $0.92 (0.69 - 1.22)$ $1.17 (0.88 - 1.57)$ Other 3.92 $-^{h}$ $0.24 - 5.6)$ $0.93 (0.57 - 1.51)$ $0.96 (0.59 - 1.55)$ Other $3.7 (2.4 - 5.6)$ $p = 0.153$ $p = 0.153$ $0.93 (0.57 - 1.51)$ $0.96 (0.59 - 1.55)$ Other $3.7 (2.4 - 5.1)$ $p = 0.153$ Other $3.7 (2.4 - 5.1)$ $p = 0.133$ ReferentReferent $ReferentVisteriol1.74 (0.92 - 1.67)1.57 (1.12 - 2.21)1.57 (1.12 - 2.21)Disteriol0.71 (3.2 - 0.2)0.13 (3.4 - 5.1)0.93 (0.57 - 1.67)0.56 (0.47 - 0.96)Urgent2.74 - 3.2P = 0.135ReferentReferentUrgent2.5452.9 (.1 - 4.1)0.71 (0.50 - 1.02)0.67 (0.47 - 0.96)Urgent2.5452.9 (.1 - 4.1)0.71 (0.50 - 1.02)0.67 (0.47 - 0.96)Urgent2.74 - 2.3P = 0.135ReferentReferentUrgent1.31 (3.4 - 5.1)1.31 (3.4 - 5.1)0.51 (0.52 - 1.32)0.51 (0.52 - 1.32)Urgent2.9 (1.1 - 7.3)P = 0.1321.31 (0.8 - 2.92)0.61$		(2.9–9.2)	Referent	leferent
Race - - Referent White 7933 40 (3.2 - 4.9) Referent Referent White 7933 40 (3.2 - 4.9) Referent Referent Black 2,097 36 (2.9 - 4.6) 0.92 (0.69 - 1.22) 1.17 (0.88 - 1.57) Other 395 - $ -$ Not stated 4.296 3.7 (2.4 - 5.6) 0.93 (0.57 - 1.51) 0.96 (0.59 - 1.55) Days of hospital stay 3.7 (2.4 - 5.6) $ -$ Z days 6,746 3.4 (2.6 - 4.3) Referent Referent Referent Z days 7975 4.2 (3.4 - 5.1) $ -$ Z days 7975 3.4 (2.6 - 4.3) Referent Referent $-$ Urgent 9.120 4.1 (3.4 - 5.1) $ -$ Urgent 9.120 4.1 (3.4 - 5.1) $ -$ Urgent 9.1 (0.5 - 1.6 (1.46 (1.08-1.96) 1.45 (1.09-1.93) 8.2	(7.2-9.4)	0.99 (0.86–1.14)	.00 (0.86–1.15)
White 7,933 4,0 (3,2 - 4,9) Referent Referent Black 2,097 3.6 (2,9 - 4.6) 0.92 (0.69 - 1.23) 1.17 (0.88 - 1.57) Other 395 $^{-1}$ 0.92 (0.69 - 1.23) 1.17 (0.88 - 1.57) Other 395 $^{-1}$ 0.93 (0.57 - 1.51) 0.96 (0.59 - 1.55) Not stated 4,296 3.7 (2,4 - 5.6) 0.93 (0.57 - 1.51) 0.96 (0.59 - 1.55) Ave stated 4,296 3.4 (2.6 - 4.3) $^{-1}$ 0.93 (0.57 - 1.51) 0.96 (0.59 - 1.55) Pays of hospital stay 5.7 (3,4 - 5.1) $^{-1}$ $^{-1}$ 0.93 (0.57 - 1.51) 0.96 (0.59 - 1.55) Pays of hospital stay $^{-1}$ $^{-1}$ $^{-1}$ $^{-1}$ $^{-1}$ Pays of hospital stay $^{-1}$ $^{-1}$ $^{-1}$ $^{-1}$ $^{-1}$ Pays of hospital stay $^{-1}$ $^{-1}$ $^{-1}$ $^{-1}$ $^{-1}$ Pays of hospital stay $^{-1}$ $^{-1}$ $^{-1}$ $^{-1}$ $^{-1}$ $^{-1}$ Ver $^{-1}$		6—		
Black 2,097 36 (2.9-46) 092 (0.69-1.22) 1.17 (0.88-1.57) Other 395 $^{-1}$ $^{-2}$ $^{-1}$ $^{-1}$ $^{-1}$ Other 395 $^{-1}$ $^{-1}$ $^{-1}$ $^{-1}$ $^{-1}$ $^{-1}$ Not stated $4,296$ $3.7 (2.4-56)$ $^{-1}$ $^{-2}$ $^{-2}$ $^{-2}$ Part $^{-1}$ $^{-2}$ $^{-2}$ $^{-2}$ $^{-2}$ $^{-2}$ Part $^{-1}$ $^{-2}$ $^{-2}$ $^{-2}$ $^{-2}$ $^{-2}$ Part $^{-2}$ $^{-2}$ $^{-2}$ $^{-2}$ $^{-2}$ $^{-1}$ Part $^{-2}$ $^{-2}$ $^{-2}$ $^{-2}$ $^{-2}$ $^{-2}$ Part $^{-2}$ $^{-2}$ $^{-1}$ $^{-2}$ $^{-1}$ $^{-1}$ $^{-1}$ Part $^{-1}$ $^{-1}$ $^{-1}$ $^{-1}$ $^{-1}$ $^{-1}$ $^{-1}$ Part $^{-1}$ $^{-1}$	Referent Referent 8.5	(7.4–9.9)	Referent	teferent
Other 395 h $^{-}$ $^{-}$ Not stated 4,296 3.7 (2,4–5.6) 0.93 (0.57–1.51) 0.96 (0.59–1.55) Pays of hospital stay $P=0.153$ Referent Referent ≥ 7 days 5.7 day 3.4 (2.6 - 4.3) Referent Referent ≥ 7 days 7.975 3.4 (2.6 - 4.3) Referent Referent ≥ 7 days 7.975 4.2 (3.4 - 5.1) 1.24 (0.92 - 1.67) 1.57 (1.12 - 2.21) < 7 days 7.975 4.1 (3.4 - 5.1) $P=0.135$ Referent Referent < 7 days 7.975 9.120 4.1 (3.4 - 5.1) 1.24 (0.92 - 1.67) 0.53 (0.47 - 0.96) Urgent 2.54 (3.7 - 7.7) $P=0.135$ Referent Referent Urgent 1.643 2.9 (1.1 - 7.3) 0.71 (0.50 - 1.02) 0.53 (0.47 - 0.96) Urgent 2.54 (3.7 - 7.7) 1.31 (0.86 - 1.98) 1.33 (0.88 - 2.07) Not stated 1.413 5.4 (3.7 - 7.7) 1.31 (0.86 - 1.98) 1.33 (0.88 - 2.07) Not stated <td< td=""><td>0.92 (0.69-1.22) 1.17 (0.88-1.57) 7.4</td><td>(6.6 – 8.4)</td><td>0.87 (0.72-1.05)</td><td>.10 (0.91–1.32)</td></td<>	0.92 (0.69-1.22) 1.17 (0.88-1.57) 7.4	(6.6 – 8.4)	0.87 (0.72-1.05)	.10 (0.91–1.32)
Not stated 4,296 3,7 (2,4-5.6) 0,93 (0,57-1.51) 0,96 (0.59-1.55) Pays of hospital stay $P=0.153$ $P=0.153$ P=0.153 P=0.153 Seferent ≥ 7 days $5,74$ $3,4 (2,6-4,3)$ $P=0.135$ Referent Referent ≥ 7 days $5,975$ $4,236-3.1$ $P=0.135$ Referent Referent < 7 days $7,975$ $4,24-5.1$ $P=0.135$ Referent Referent < 7 days $2,945$ $2,9(1-4.2)$ $P=0.135$ Referent Referent Urgent $2,545$ $2,9(1-4.2)$ $P=0.135$ Referent Referent Urgent $2,545$ $2,9(1-7.2)$ $0,71(0,50-1,02)$ $0.57(0,47-0.96)$ Urgent $2,543$ $2,9(1-7.2)$ $0,71(0,50-1,02)$ $0.57(0,47-0.96)$ Urgent $2,543$ $0,21(0,50-1,02)$ $0.57(0,47-0.96)$ $0.57(0,47-0.96)$ Urgent $2,9(1,1,7,3)$ $0.54(1,0,7,0)$ $0.71(0,50-1,02)$ $0.57(0,47-0.96)$ Not stated $1,433$ $2,9(1,1,2,2,3)$	- 10.6	5 (9.2–12.2)	1.24 (1.01–1.54)	.36 (1.14–1.64) ^f
Pays of hospital stay $P=0.153$ ≥ 7 days $6,746$ $3.4(26-4.3)$ Referent Referent ≥ 7 days $6,746$ $3.4(26-4.3)$ Referent Referent < 7 days $7,975$ $4.2(3-5.1)$ $1.24(0.92-1.67)$ $1.57(1.12-2.21)$ Type of Admission $7,975$ $4.2(34-5.1)$ $P=0.135$ Referent $8.67(0.47-0.26)$ Type of Admission $2,545$ $2.9(2.1-4.1)$ $P=0.135$ $8.67(0.47-0.26)$ Urgent $2,545$ $2.9(2.1-4.1)$ $0.71(0.50-1.02)$ $0.67(0.47-0.26)$ Urgent $2,545$ $2.9(1.1-7.3)$ $0.71(0.50-1.02)$ $0.67(0.47-0.26)$ Urgent $1,413$ $5.4(3.7-7.7)$ $0.57(0.61-1.26)$ $0.57(0.47-0.26)$ Not stated $1,413$ $5.4(3.7-7.7)$ $0.59(0.26-1.86)$ $0.53(0.24-1.61)$ Not stated $1,413$ $5.4(3.7-7.7)$ $0.59(0.26-1.86)$ $0.57(0.47-0.96)$ Not stated $1,712$ $2.9(1.17-3)$ $0.51(0.50-1.82)$ $0.57(0.47-0.96)$ Not stated $1,213$	0.93 (0.57-1.51) 0.96 (0.59-1.55) 7.7	(6.5 – 9.0)	0.90 (0.72-1.12)	.93 (0.75-1.17)
$\geq 7 days$ $6,746$ $34,(26-4,3)$ Referent Referent $< 7 days$ $7,975$ $42,(34-5,1)$ $124,(0.92-1.6,7)$ $157,(1.12-2.21)$ Type of Admission $P=0.135$ $P=0.135$ Referent Referent Urgent $2,545$ $2,9(1-4,1)$ $P=0.135$ Referent $Referent$ Urgent $2,545$ $2,9(1-4,1)$ $Referent$ $Referent$ $Referent$ Urgent $2,545$ $2,9(1-7,3)$ $Referent$ $Referent$ $Referent$ Urgent $1,413$ $5,4(3,7-7,7)$ $0.21,(0.50-1,02)$ $0.63,(0.24-1.61)$ Not stated $1,413$ $5,4(3,7-7,7)$ $P=0.001$ $1.31,(0.86-1.98)$ $1.33,(0.88-2.02)$ Not stated $1,413$ $5,4(3,7-7,7)$ $P=0.001$ $1.31,(0.86-1.98)$ $1.33,(0.88-2.02)$ Not stated $1,413$ $5,4(3,7-7,7)$ $P=0.001$ $1.31,(0.86-1.98)$ $1.33,(0.88-2.02)$ Not stated $1,213$ $3,2,7-4,22$ $P=0.001$ $1.31,(0.86-1.98)$ $1.33,(0.88-2.02)$		P = 0.168		
<7 days $7,975$ 4.2 $(3.4-5.1)$ 1.24 $(0.92-1.67)$ 1.57 $(1.12-2.21)$ Type of Admission $P=0.135$ $P=0.135$ $P=0.135$ $P=0.135$ $I.57$ $(1.12-2.21)$ Type of Admission $9,120$ 4.1 $(3.4-5.1)$ $P=0.135$ $Referent$ $Referent$ Urgent $2,545$ 2.9 $(2.1-4.1)$ 0.71 $(0.50-1.02)$ 0.67 $(0.47-0.96)$ Urgent $1,643$ 2.9 $(1.1-7.3)$ 0.71 $(0.50-1.02)$ 0.67 $(0.47-0.96)$ Urgent $1,643$ 2.9 $(1.1-7.3)$ 0.71 $(0.50-1.02)$ 0.67 $(0.47-0.96)$ Urgent $1,643$ 2.9 $(1.1-7.3)$ 0.71 $(0.50-1.02)$ 0.67 $(0.47-0.96)$ Not stated $1,413$ 5.4 $(3.7-7.7)$ 0.69 $(0.26-1.86)$ 0.63 $(0.24-1.61)$ Not stated $1,413$ 5.4 $(3.7-7.7)$ $P=0.001$ 1.31 $(0.86-1.96)$ 1.33 $(0.88-2.02)$ Not stated 1.233 3.3 $(2.7-4.2)$ $P=0.001$ 1.31 $(0.86-1.96)$ 1.33 $(0.88-2.02)$ No 1.2233 3.3 $(2.7-4.2)$ $P=0.012$ 1.31 $(0.86-1.96)$ 1.33 $(0.88-2.02)$ No 1.233 <td>Referent Referent 7.6</td> <td>(6.5 – 8.8)</td> <td>Referent</td> <td>teferent</td>	Referent Referent 7.6	(6.5 – 8.8)	Referent	teferent
Type of Admission $P=0.135$ Emergency $9,120$ $4.1(34-5.1)$ Referent Referent Urgent $2,545$ $2,9(21-4.1)$ $0,71(0.50-1.02)$ $0.67(0.47-0.96)$ Urgent $2,545$ $2,9(1.1-7.3)$ $0,71(0.50-1.02)$ $0.67(0.47-0.96)$ Urgent $1,643$ $2,9(1.1-7.3)$ $0.69(0.26-1.85)$ $0.63(0.24-1.61)$ Not stated $1,413$ $5,4(3.7-7.7)$ $0.69(0.26-1.98)$ $0.63(0.24-1.61)$ Not stated $1,413$ $5,4(3.7-7.7)$ $0.69(0.26-1.85)$ $0.63(0.24-1.61)$ Not stated $1,413$ $5,4(3.7-7.7)$ $P=0.02$ $1.31(0.86-1.98)$ $1.33(0.88-2.02)$ Not stated $1,213$ $3.3(2.7-4.2)$ $P=0.001$ $1.31(0.86-1.98)$ $1.33(0.88-2.02)$ No $12,233$ $3.3(2.7-4.2)$ $P=0.001$ $1.31(0.86-1.98)$ $1.33(0.88-2.02)$ No $12,233$ $3.3(2.7-4.2)$ $P=0.012$ $1.31(0.86-1.98)$ $1.33(0.88-2.02)$ No $12,233$ $3.3(2.7-4.2)$ $P=0.012$ $1.30(1.17-3.13)$	1.24 (0.92-1.67) 1.57 (1.12-2.21) 8.8	(7.7-10.0)	1.15 (0.94–1.41)	.43 (1.15–1.76)
Emergency $9,120$ $4,1(3,4-5,1)$ ReferentReferentUrgent $2,545$ $2,9(2,1-4,1)$ $0,71(0,50-1,02)$ $0.67(0,47-0.96)$ Urgent $1,643$ $2,9(1,1-7,3)$ $0,69(0,26-1,85)$ $0.63(0,24-1,61)$ Flective $1,643$ $5,4(3,7-7,7)$ $0.69(0,26-1,85)$ $0.63(0,24-1,61)$ Not stated $1,413$ $5,4(3,7-7,7)$ $0.69(0,26-1,89)$ $1.33(0,88-2,02)$ Amerer $P<0.001$ $1,213$ $3,3(2,7-4,2)$ $P<0.001$ $ReferentNo12,2333,3(2,7-4,2)P<0.001ReferentReferentNo12,2333,3(2,7-4,2)P<0.001ReferentReferentNo12,2333,3(2,7-4,2)P<0.001ReferentReferentNo12,2333,3(2,7-4,2)P<0.001ReferentReferentNo12,2333,3(2,7-4,2)P<0.001ReferentReferentNo12,2333,3(2,7-4,2)P=0.012ReferentReferentNo1,28983,6(3,0-4,3)P=0.012ReferentReferentNe1,8237,1(4,3-11,6)2,00(1,1,7-3,4)2,20(1,28-3,77)$		P = 0.228		
Urgent $2,545$ $2.9 (2.1-4.1)$ $0.71 (0.50-1.02)$ $0.67 (0.47-0.96)$ Flective $1,643$ $2.9 (1.1-7.3)$ $0.69 (0.26-1.85)$ $0.63 (0.24-1.61)$ Not stated $1,413$ $5.4 (3.7-7.7)$ $0.59 (0.26-1.89)$ $1.33 (0.88-2.02)$ Not stated $1,413$ $5.4 (3.7-7.7)$ $P<0.001$ $1.31 (0.86-1.98)$ $1.33 (0.88-2.02)$ Cancer $P<0.001$ $P<0.001$ $P<0.001$ $P<0.001$ $P<0.001$ $P<0.001$ No $12,233$ $3.3 (2.7-4.2)$ $P<0.001$ ReferentReferentNo $12,233$ $3.3 (2.7-4.2)$ $P<0.001$ $P<0.001$ $P<0.001$ No $12,233$ $3.3 (2.7-4.2)$ $P<0.001$ $P=0.012$ $P=0.012$ No $1,2898$ $3.6 (3.0-4.3)$ $P<0.012$ $P=0.012$ $P=0.012$ Ves $1,823$ $7.1 (4.3-11.6)$ $2.00 (1.17-3.4)$ $2.20 (1.28-3.77)$	Referent Referent 8.4	(7.5–9.4)	Referent	leferen t
Elective $1,643$ $2.9 (1.1-7.3)$ $0.69 (0.26-1.85)$ $0.63 (0.24-1.61)$ Not stated $1,413$ $5.4 (3.7-7.7)$ $1.31 (0.86-1.98)$ $1.33 (0.88-2.02)$ Cancer $1,213$ $3.3 (2.7-4.2)$ $P<0.001$ $1.31 (0.86-1.98)$ $1.33 (0.88-2.02)$ No $12,233$ $3.3 (2.7-4.2)$ $P<0.001$ ReferentReferentVes $2,488$ $7.5 (6.1-9.2)$ $2.25 (1.62-3.13)$ $2.28 (1.68-3.09)$ Ves $2,488$ $7.5 (6.1-9.2)$ $P=0.012$ $P=0.012$ No $1,2898$ $3.6 (3.0-4.3)$ ReferentReferentVes $1,823$ $7.1 (4.3-11.6)$ $2.00 (1.17-3.43)$ $2.20 (1.28-3.77)$	0.71 (0.50-1.02) 0.67 (0.47-0.96) 7.4	(6.0-9.1)	0.88 (0.70-1.11) (.84 (0.67–1.05)
Not stated $1,413$ $5,4(3,7-7,7)$ $131(0.86-1.98)$ $1.33(0.88-2.02)$ Cancer $P<0.001$ $P<0.001$ $1.33(0.88-2.02)$ No $12,233$ $3.3(2.7-4.2)$ $P<0.001$ $Referent$ Ves $2,488$ $7.5(6.1-9.2)$ Referent Referent Ves $2,488$ $7.5(6.1-9.2)$ $2.25(1.62-3.13)$ $2.28(1.68-3.09)$ Penumonia $P=0.012$ Referent Referent Referent No $1,829$ $3.6(3.0-4.3)$ $Referent Referent Ves 1,823 7.1(4.3-11.6) 2.00(1.17-3.43) 2.20(1.28-3.77) $	0.69 (0.26-1.85) 0.63 (0.24-1.61) 7.6	(5.2-10.9)	0.90 (0.62-1.31)	.93 (0.65–1.34)
P<0.001 P<0.001 No 12,233 3.3 (2.7-4.2) Referent Referent Yes 2.488 7.5 (6.1-9.2) 2.25 (1.62-3.13) 2.28 (1.68-3.09) Penumonia P=0.012 2.25 (1.62-3.13) 2.28 (1.68-3.09) No 12,898 3.6 (3.0-4.3) P=0.012 2.28 (1.68-3.09) Yes 1,823 7.1 (4.3-11.6) 2.00 (1.17-3.43) 2.20 (1.28-3.77)	1.31 (0.86–1.98) 1.33 (0.88–2.02) 10.C) (8.1–12.3)	1.19 (0.94–1.51)	.23 (0.96–1.56)
No $12,233$ $3.3(2.7-4.2)$ Referent Referent Yes $2,488$ $7.5(6.1-9.2)$ $2.25(1.62-3.13)$ $2.28(1.68-3.09)$ Peumonia $P=0.012$ Referent Referent Referent No $1,2,898$ $3.6(3.0-4.3)$ $P=0.012$ $2.25(1.62-3.13)$ $2.28(1.68-3.09)$ Vev $1,823$ $7.1(4.3-11.6)$ $2.00(1.17-3.43)$ $2.20(1.28-3.77)$		P<0.001		
Yes $2,488$ 7.5 (6.1–9.2) 2.25 (1.62–3.13) 2.28 (1.68–3.09)Pneumonia $P=0.012$ $P=0.012$ ReferentReferentNo12,898 3.6 ($3.0-4.3$)ReferentReferentYes1,823 7.1 ($4.3-11.6$) 2.00 ($1.17-3.43$) 2.20 ($1.28-3.77$)	Referent Referent 7.1	(6.3-8.1)	Referent	teferent
Pneumonia P=0.012 No 12,898 3.6 (3.0-4.3) Referent Referent Yes 1,823 7.1 (4.3-11.6) 2.00 (1.17-3.43) 2.20 (1.28-3.77)	2.25 (1.62-3.13) 2.28 (1.68-3.09) 14.1	(12.5-15.8)	1.97 (1.64–2.37)	1.10 (1.74–2.53)
No 12,898 3.6 (3.0-4.3) Referent Referent Yes 1,823 7.1 (4.3-11.6) 2.00 (1.17-3.43) 2.20 (1.28-3.77)		P<0.001		
Yes 1,823 7.1 (4.3–11.6) 2.00 (1.17–3.43) 2.20 (1.28–3.77)	Referent Referent 7.5	(6.6 - 8.4)	Referent	leferent
	2.00 (1.17-3.43) 2.20 (1.28-3.77) 13.7	7 (11.5–16.3)	1.83 (1.50-2.24)	.79 (1.48–2.17)
Fractures		P<0.001		
No 14,354 3.9 (3.3–4.7) – – –	- 7.9	(7.2–8.8)	Referent	teferent
Yes 367 – – – –	17.8	8 (13.1–23.7)	2.24 (1.67-3.00)	:32 (1.68–3.20)

drate ratio. •Rate ratio from log-linear regression model that adjusted for age, sex, race, days of stay, type of admission, cancer, pneumonia, and fractures. •Referent rate ratio = 1.00. ^BEstimate may not be reliable due to underreporting of race information. ^NUnstable estimate due to small subgroup size. doi:10.1371/journal.pone.0034048.t002

hospital stay, without cancer, pneumonia, or fractures after adjustment of all covariates (Table 2).

Discussion

Previous studies have assessed many correlates of in-hospital death among PE patients in healthcare settings [21-24], our study expanded previous research by assessing in-hospital deaths with a PE diagnosis encompassing first-listed and any-listed ICD-9 diagnostic codes during 2001-2008. The associations of cancer, pneumonia, and fractures with in-hospital deaths among a nationally representative sample of hospitalizations with a firstlisted and any-listed PE diagnosis in the United States during the study period have not been reported in the past. Such observational evidence is valuable for identifying risk factors that may place patients at an increased risk of death and for improving clinical assessment and management to prevent fatal PE. Regardless of the listing position, we observed an increased likelihood of in-hospital death in subgroups of hospitalizations with advanced ages, less than 7 days of hospital stay, cancer, pneumonia, or fractures (except for first-listed PE), when compared to the reference groups with ages 1-49 years, 7 days or more of hospital stay, without cancer, pneumonia, or fractures while adjusting for all covariates. In addition, we observed an increased likelihood of in-hospital death for first-listed PE in hospitalizations of women when compared to those of men. However, the exact reason for this increase remained unknown, additional research may be needed. Interestingly, regardless of the listing position, we did not find that type of admission (e.g., emergency admission) was a factor independently associated with in-hospital death with a PE diagnosis.

Some results of this study were consistent with evidence that mortality rates were high among patients with advanced ages or co-morbid conditions such as cancer. Recent data suggested that a decline in the overall case-fatality rate of US hospitalizations with a PE diagnosis could be attributable to a combination of an increased number of PE diagnoses resulting from the widely used computed tomography pulmonary angiography (e.g., detection of asymptomatic PE or small peripheral emboli) together with more effective treatment and fewer complications [13,20,30–32]. Regardless, the strength of associations between the correlates and in-hospital death remained essentially unchanged during the study period, when survey year was used as an additional stratification variable or as a covariate in the regression models (data not shown).

The results of our study provide support for enhancing efforts toward identifying and implementing appropriate preventive strategies among hospitalized patients, including those with comorbid conditions such as cancer, pneumonia, and fractures in healthcare settings [33]. Because of the disease severity, fatal PE may occur early during a hospital stay and may be undiagnosed, clinicians must be attentive to identify PE patients. Because the case-fatality rate was higher among hospitalizations of a shorter hospital stay than those of a longer stay, our results suggest that fatal PE may occur early after a hospital admission [34,35]. As such, clinical assessment, diagnostic evaluation, and appropriate treatment for PE should be performed early and promptly among hospitalized patients [34,36,37].

Our study has some limitations. Cross-sectional surveys are not designed to evaluate a cause-effect relationship. The NHDS

References

hospitalizations rates do not necessarily reflect rates per person, as hospitalizations of recurrent PE patients could be included. Because asymptomatic PE patients with other co-morbid conditions might be undiagnosed or misdiagnosed, or PE diagnosis might have not been made before death occurred, hospitalizations for these patients might not have been included in our study. Due to underreporting of race in the NHDS, extra caution is needed for making any statistical inference regarding race as such estimates may not be reliable [28]. Even though we adjusted for many covariates in the study, we were unable to control for potential anticoagulant therapies, medications, and other comorbidities that may affect short-term mortality in PE patients, due to the constraints of administrative datasets.

The results from this analysis and earlier study suggest that a majority of in-hospital deaths with a PE diagnosis could be attributable to concurrent PE and other health conditions [13]. Presently, there is a paucity of information concerning the clustering of risk factors that may hinder timely diagnosis, obscure clinical assessment and management, and exacerbate the risk of morbidity, mortality, and impaired health-related quality of life in PE patients [38-42]. Given that PE is a continuing clinical and public health concern in the United States, additional research is needed to elucidate amenable or manageable risk factors that are associated with devastating health consequences including death among PE patients. As the US population is aging, the coexistence of two or more chronic health conditions is a growing public health problem and poses enormous challenges for clinicians, patients, and healthcare systems [43-45]. To effectively reduce PE-related mortality and to improve overall health and well-being among most PE patients, more epidemiologic research and multimorbidity intervention studies are needed in order to deliberate, investigate, inform, and advance evidence-based practice in healthcare settings where integrated interventions may be coordinated and delivered to patients with multiple health conditions including PE [46-48].

In conclusion, the results of this study provide support for identifying, developing, and implementing effective, evidencebased clinical assessment and management strategies to reduce PE-related morbidity and mortality among hospitalized PE patients who may have concurrent health conditions including cancer, pneumonia, and fractures.

Acknowledgments

The authors of this study sincerely thank Stephanie Robinson, MPH of the Research Data Center, National Center for Health Statistics, Centers for Disease Control and Prevention, for coordinating the review of our research proposal and providing administrative and technical support for accessing the data. **Disclaimer:** The findings and conclusions in this paper are those of the authors and do not necessarily represent the views of the Research Data Center, the National Center for Health Statistics, or the Centers for Disease Control and Prevention.

Author Contributions

Conceived and designed the experiments: JT SDG WCH. Performed the experiments: JT SDG AMG NLR WCH HKA. Analyzed the data: JT. Contributed reagents/materials/analysis tools: JT SDG AMG NLR WCH HKA. Wrote the paper: JT SDG. Critical revision of the paper for important intellectual content: JT SDG AMG NLR WCH HKA. Administrative, technical, material support, and study supervision: AMG HKA.

 Heit JA (2005) Venous thromboembolism: disease burden, outcomes and risk factors. J Thromb Haemost 3: 1611–7.

Rosendaal FR (2005) Venous Thrombosis: The Role of Genes, Environment, and Behavior. Hematology 2005: 1–12.

- Goldhaber SZ (2010) Risk factors for venous thromboembolism. J Am Coll Cardiol 56: 1–7.
- Stein PD, Matta F (2010) Epidemiology and incidence: the scope of the problem and risk factors for development of venous thromboembolism. Clin Chest Med 31: 611–28.
- DHHS (2008) The Surgeon General's Call to Action to Prevent Deep Vein Thrombosis and Pulmonary Embolism. Office of the Surgeon General. U.S. Department of Health & Human Services. Washington, DC. Availabe: http:// www.surgeongeneral.gov/topics/deepvein/calltoaction/call-to-action-on-dvt-2008.pdf. Accessed 2011 Aug 8.
- Zhu T, Martinez I, Emmerich J (2009) Venous thromboembolism: risk factors for recurrence. Arterioscler Thromb Vasc Biol 29: 298–310.
- Klok F, van Kralingen K, van Dijk APJ, Heyning F, Vliegen H, et al. (2010) Quality of life in long-term survivors of acute pulmonary embolism. Chest 138: 1432–40.
- Rubenfire M, Bayram M, Hector-Word Z (2007) Pulmonary hypertension in the critical care setting: classification, pathophysiology, diagnosis, and management. Crit Care Clin 23: 801–34, vi–vii.
- Cohen AT, Alikhan R, Arcelus JI, Bergmann JF, Haas S, et al. (2005) Assessment of venous thromboembolism risk and the benefits of thromboprophylaxis in medical patients. Thromb Haemost 94: 750–9.
- Geerts W (2009) Prevention of venous thromboembolism: a key patient safety priority. J Thromb Haemost 7 Suppl 1: 1–8.
- Alikhan R, Cohen AT, Combe S, Samama MM, Desjardins L, et al. (2004) Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study. Arch Intern Med 164: 963–8.
- CDC (2010) National Hospital Discharge Survey: 2007 Summary. Available: http://www.cdc.gov/nchs/data/nhsr/nhsr029.pdf. National Health Statistics Reports 29. Accessed 2011 Aug 8.
- Tsai J, Grosse SD, Grant AM, Hooper WC, Atrash HK (2012) Trends in In-Hospital Deaths Among Hospitalizations With Pulmonary Embolism. Arch Intern Med. doi:10.1001/archinternmed.2012.198.
- Alikhan R, Peters F, Wilmott R, Cohen AT (2004) Fatal pulmonary embolism in hospitalised patients: a necropsy review. J Clin Pathol 57: 1254–7.
- Heit JA (2008) The epidemiology of venous thromboembolism in the community. Arterioscler Thromb Vasc Biol 28: 370–2.
- Stein PD, Beemath A, Meyers FA, Kayali F, Skaf E, et al. (2006) Pulmonary embolism as a cause of death in patients who died with cancer. Am J Med 119: 163–5.
- Horlander KT, Mannino DM, Leeper KV (2003) Pulmonary embolism mortality in the United States, 1979–1998: an analysis using multiple-cause mortality data. Arch Intern Med 163: 1711–7.
- Stein PD, Kayali F, Olson RE (2004) Estimated case fatality rate of pulmonary embolism, 1979 to 1998. Am J Cardiol 93: 1197–9.
- Stein PD, Kayali F, Olson RE (2004) Regional differences in rates of diagnosis and mortality of pulmonary thromboembolism. Am J Cardiol 93: 1194–7.
- Wiener RS, Schwartz LM, Woloshin S (2011) Time trends in pulmonary embolism in the United States: evidence of overdiagnosis. Arch Intern Med 171: 831–7.
- Stein PD, Matta F (2012) Case fatality rate with pulmonary embolectomy for acute pulmonary embolism. Am J Med 125: 471–7.
- Chughtai HL, Janjua M, Matta F, Jaweesh F, Stein PD (2011) Predictors of inhospital mortality in patients receiving thrombolytic therapy for pulmonary embolism. Clin Appl Thromb Hemost 17: 656–8.
- Stein PD, Matta F, Keyes DC, Willyerd GL (2012) Impact of Vena Cava Filters on In-hospital Case Fatality Rate from Pulmonary Embolism. Am J Med 125: 478–84.
- Ho KM, Burrell M, Rao S, Baker R (2010) Incidence and risk factors for fatal pulmonary embolism after major trauma: a nested cohort study. British journal of anaesthesia 105: 596–602.
- Centers for Disease Control (2011) National Hospital Discharge Survey (NHDS). National Center for Health Statistics (NCHS), Centers for Disease Control and Prevention, U.S. Department of Health and Human Services,

Atlanta, Georgia. Available: http://www.cdc.gov/nchs/index.htm2011. Accessed 2011 Aug 8.

- Centers for Disease Control (2011) Research Data Center (RDC). National Center for Health Statistics (NCHS), Centers for Disease Control and Prevention (CDC), U.S. Department of Health and Human Services, Atlanta, Georgia. Available: http://www.cdc.gov/rdc/2011. Accessed 2011 Aug 8.
- 27. Korn E, Graubard B (1999) Analysis of Health Surveys. New York: John Wiley and Sons, Inc.
- Kozak LJ (1995) Underreporting of race in the National Hospital Discharge Survey. National Center for Health Statistics (NCHS), Centers for Disease Control and Prevention. Report No.: Series 10, Number 225.
- Brogan D (2005) Software for Sample Survey Data, Misuse of Standard Packages. Encyclopedia of Biostatistics. 8-Set: 5057–64.
- DeMonaco N, Dang Q, Kapoor W, Ragni M (2008) Pulmonary embolism incidence is increasing with use of spiral computed tomography. The American journal of medicine 121: 611–7.
- Prasad V, Rho J, Cifu A (2012) The Diagnosis and Treatment of Pulmonary Embolism: A Metaphor for Medicine in the Evidence-Based Medicine Era. Arch Intern Med. doi:10.1001/archinternmed.2012.195.
- Stein PD, Matta F (2012) Thrombolytic therapy in unstable patients with acute pulmonary embolism: saves lives but underused. Am J Med 125: 465–70.
- Nicolaides A, Breddin H, Fareed J, Goldhaber S, Haas S, et al. (2006) Prevention and treatment of venous thromboembolism. International Consensus Statement (guidelines according to scientific evidence). Int Angiol 25: 101–61.
- Agnelli G, Becattini C (2010) Acute pulmonary embolism. N Engl J Med 363: 266–74.
- Cushman M (2007) Epidemiology and risk factors for venous thrombosis. Semin Hematol 44: 62–9.
- 36. Tapson VF (2008) Acute pulmonary embolism. N Engl J Med 358: 1037-52.
- Stein PD, Sostman HD, Dalen JE, Bailey DL, Bajc M, et al. (2011) Controversies in diagnosis of pulmonary embolism. Clin Appl Thromb Hemost 17: 140–9.
- Abunasser J, Tejada J, Foley R (2012) The diagnosis and management of pulmonary embolism. Connecticut medicine 76: 5–14.
- van Es J, Douma RA, Gerdes VEA, Kamphuisen PW, Buller HR (2010) Acute pulmonary embolism. Part 2: treatment. Nat Rev Cardiol 7: 613–22. doi: 10.1038/nrcardio.2010.141.
- Douma RA, Kamphuisen PW, Buller HR (2010) Acute pulmonary embolism. Part 1: epidemiology and diagnosis. Nat Rev Cardiol 7: 585–96. doi:10.1038/ nrcardio.2010.106.
- Klok FA, Cohn DM, Middeldorp S, Scharloo M, Buller HR, et al. (2010) Quality of life after pulmonary embolism: validation of the PEmb-QoL Questionnaire. J Thromb Haemost 8: 523–32.
- Smith SB, Geske JB, Morgenthaler TI (2012) Risk Factors Associated with Delayed Diagnosis of Acute Pulmonary Embolism. The Journal of Emergency Medicine 42: 1–6.
- Fortin M, Soubhi H, Hudon C, Bayliss EA, van den Akker M (2007) Multimorbidity's many challenges. BMJ [Editorial] 334: 1016–7.
- Boyd CM, Darer J, Boult C, Fried LP, Boult L, et al. (2005) Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: implications for pay for performance. JAMA 294: 716–24.
- Smith SM, O'Dowd T (2007) Chronic diseases: what happens when they come in multiples? The British Journal of General practice 57: 268–70.
- Boyd CM, Fortin M (2010) Future of Multimorbidity Research: How Should Understanding of Multimorbidity Inform Health System Design? Public Health Reviews 32: 451–74.
- Mercer SW, Smith SM, Wyke S, O'Dowd T, Watt GC (2009) Multimorbidity in primary care: developing the research agenda. Family practice [Editorial] 26: 79–80.
- DHHS (2010) Multiple Chronic Conditions: A Strategic Framework. Optimum Health and Quality of Life for Individuals with Multiple Chronic Conditions. US Department of Health and Human Services (DHHS), Washington, DC.